- Home
- SKYE vs REFI Comparison
SKYE vs REFI Comparison
Compare SKYE & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | REFI |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 253.6M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKYE | REFI |
|---|---|---|
| Price | $0.77 | $11.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 184.9K | 144.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $48,857,628.00 |
| Revenue This Year | N/A | $17.47 |
| Revenue Next Year | N/A | $0.06 |
| P/E Ratio | ★ N/A | $49.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $10.74 |
| 52 Week High | $5.75 | $14.97 |
Technical Indicators
Market Signals| Indicator | SKYE | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 39.18 |
| Support Level | $0.71 | $10.74 |
| Resistance Level | $0.83 | $12.45 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 7.91 | 8.59 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.